Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16770343 | 0.89 | SIRT1 (0.39) | SPHK1SPHK2 | |
| SCHEMBL16847756 | 0.89 | SPHK1 (0.40) | SPHK1SPHK2FURINCITKLKB1 | |
| SCHEMBL16392367 | 0.89 | SPHK1 (0.40) | SPHK1SPHK2FURINCITKLKB1 | |
| SCHEMBL20739105 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN | |
| SCHEMBL12944390 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN | |
| SCHEMBL7607468 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN | |
| SCHEMBL20158427 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN | |
| SCHEMBL22315797 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN | |
| SCHEMBL84332 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN | |
| SCHEMBL15692085 | 0.87 | NPY4R (0.38) | SPHK1SPHK2FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | MACROGENICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | CD274, HRH3, CD2 | SPHK1 4599/4885SPHK2 4589/4885FURIN 3879/4885 |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | SPHK1 4575/4885SPHK2 4542/4885FURIN 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.